TPD52L2 Antibody
Description
Introduction
The TPD52L2 antibody is a diagnostic and research tool designed to detect the tumor protein D52-like 2 (TPD52L2), a protein implicated in tumor progression and immune regulation. This antibody is widely used in oncology research to study its role in cancers such as clear cell renal cell carcinoma (ccRCC), breast cancer, and glioma. Its application spans immunohistochemistry (IHC), Western blot (WB), and immunofluorescence (IF) techniques, with commercial products available from manufacturers like Proteintech, Sigma-Aldrich, and Abcam .
Mechanism of Action
TPD52L2 antibodies target the TPD52L2 protein, a member of the tumor protein D52 family, which regulates vesicle trafficking, cell proliferation, and apoptosis. Its overexpression has been linked to oncogenic pathways, including the PI3K-Akt, Wnt, and IL-17 signaling pathways, facilitating tumor growth and immune evasion .
| Pathway | Role of TPD52L2 |
|---|---|
| PI3K-Akt | Promotes cell survival and migration. |
| Wnt signaling | Enhances tumor cell proliferation. |
| IL-17 pathway | Modulates immune microenvironment. |
3.1. Immunodetection Techniques
The antibody is validated for:
-
Western blot: Detects TPD52L2 in lysates of HEK-293, MCF-7, and mouse/rat brain tissues .
-
Immunohistochemistry: Stains breast cancer and ccRCC tissues, with antigen retrieval via TE buffer (pH 9.0) .
-
Immunofluorescence: Visualizes TPD52L2 in HCT 116 and HepG2 cells .
3.2. Clinical Utility
-
Prognostic biomarker: High TPD52L2 expression correlates with poor survival in ccRCC patients .
-
Immunotherapy assessment: Associates with tumor mutation burden (TMB) and PD-L1 expression, aiding in predicting response to checkpoint inhibitors .
4.2. Dilution Recommendations
| Application | Dilution |
|---|---|
| Western blot | 1:500–1:1000 |
| Immunohistochemistry | 1:50–1:500 |
| Immunofluorescence | 1:50–1:500 |
5.1. Cancer-Specific Insights
-
ccRCC: TPD52L2 overexpression correlates with tumor grade, stage, and metastasis, serving as an independent prognostic marker .
-
Breast cancer: Transcript variant 6 (V6) promotes proliferation and migration in basal-like triple-negative breast cancer (BLBC) .
-
Glioma: High expression drives tumor aggressiveness via vesicle trafficking modulation .
